Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies
Bin Tan, Ryan Joyce, Haozhou Tan, et al.
Accounts of Chemical Research (2022) Vol. 56, Iss. 2, pp. 157-168
Open Access | Times Cited: 62

Showing 26-50 of 62 citing articles:

A SARS-CoV-2 Mpro fluorescent sensor for exploring pharmacodynamic substances from traditional Chinese medicine
Lei Han, Bing Wang, Kunhui Sun, et al.
The Analyst (2024) Vol. 149, Iss. 13, pp. 3585-3595
Closed Access | Times Cited: 2
Triflic Acid-Promoted 1,2-Amino Migration Reactions in α-Arylaminoacrylamides: Access to Substituted β-Aminoamides
Yueyi Li, Yu Wang, Rui Zhang, et al.
The Journal of Organic Chemistry (2024) Vol. 89, Iss. 12, pp. 8861-8870
Closed Access | Times Cited: 2
Crystal structures of coronaviral main proteases in complex with the non-covalent inhibitor X77
Haihai Jiang, Wen Li, Xuelan Zhou, et al.
International Journal of Biological Macromolecules (2024) Vol. 276, pp. 133706-133706
Closed Access | Times Cited: 2
The antiviral activity of a small molecule drug targeting the NSP1-ribosome complex against Omicron, especially in elderly patients
Min Shen, Ping Ding, Guangxin Luan, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 6
FlipGFP protease assay for evaluating in vitro inhibitory activity against SARS-CoV-2 Mpro and PLpro
Haozhou Tan, Yanmei Hu, Jun Wang
STAR Protocols (2023) Vol. 4, Iss. 2, pp. 102323-102323
Open Access | Times Cited: 6
Chrysin 7-O-β-D-glucuronide, a dual inhibitor of SARS-CoV-2 3CLpro and PLpro, for the prevention and treatment of COVID-19
Yi Yang, Rong Yu, Heng Xue, et al.
International Journal of Antimicrobial Agents (2023) Vol. 63, Iss. 1, pp. 107039-107039
Open Access | Times Cited: 6
Ferrocenoyl-substituted quinolinone and coumarin as organometallic inhibitors of SARS-CoV-2 3CLpro main protease
D Gräf, Nikolas Farn, Jonas Klopf, et al.
Metallomics (2023) Vol. 15, Iss. 5
Closed Access | Times Cited: 5
A comprehensive survey of coronaviral main protease active site diversity in 3D: Identifying and analyzing drug discovery targets in search of broad specificity inhibitors for the next coronavirus pandemic
Joseph H. Lubin, Samantha G. Martinusen, Christine Zardecki, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Design, synthesis, and structure-activity relationships of a novel class of quinazoline derivatives as coronavirus inhibitors
Shengchao Zhou, Kun Wang, Ziwei Hu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115831-115831
Closed Access | Times Cited: 4
Synthesis, SARS-CoV-2 main protease inhibition, molecular docking and in silico ADME studies of furanochromene-quinoline hydrazone derivatives
Blake M. Shellenberger, Olivia N. Basile, Joel Cassel, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 102, pp. 129679-129679
Closed Access | Times Cited: 1
Analysis of SARS-CoV-2 Mutations after Nirmatrelvir Treatment in a Lung Cancer Xenograft Mouse Model
Bo Min Kang, Dongbum Kim, Jinsoo Kim, et al.
Biomolecules & Therapeutics (2024) Vol. 32, Iss. 4, pp. 481-491
Open Access | Times Cited: 1
Mechanistic Insights into the Mutational Landscape of the Main Protease/3CLPro and Its Impact on Long-Term COVID-19/SARS-CoV-2 Management
Aganze Gloire-Aimé Mushebenge, Samuel Chima Ugbaja, Nonjabulo Ntombikhona Magwaza, et al.
(2024)
Open Access | Times Cited: 1
SARS-CoV-2 Mpro inhibitor identification using a cellular gain-of-signal assay for high-throughput screening
Renee Delgado, Jyoti Vishwakarma, Seyed Arad Moghadasi, et al.
SLAS DISCOVERY (2024) Vol. 29, Iss. 6, pp. 100181-100181
Open Access | Times Cited: 1
Artificial intelligence-aiding lab-on-a-chip workforce designed oral [3.1.0] bi and [4.2.0] tricyclic catalytic interceptors inhibiting multiple SARS-CoV-2 protomers assisted by double-shell deep learning
Surachate Kalasin, Werasak Surareungchai
RSC Advances (2024) Vol. 14, Iss. 37, pp. 26897-26910
Open Access | Times Cited: 1
Perspective for Drug Discovery Targeting SARS Coronavirus Methyltransferases: Function, Structure and Inhibition
Xin Li, Yongcheng Song
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 21, pp. 18642-18655
Closed Access | Times Cited: 1
Sunflower Trypsin Monocyclic Inhibitor Selected for the Main Protease of SARS-CoV-2 by Phage Display
Graziele Cristina Ferreira, Verônica de Moraes Manzato, Débora Noma Okamoto, et al.
Biological and Pharmaceutical Bulletin (2024) Vol. 47, Iss. 11, pp. 1813-1822
Open Access | Times Cited: 1
De Novo Discovery of a Noncovalent Cell-Penetrating Bicyclic Peptide Inhibitor Targeting SARS-CoV-2 Main Protease
Yahong Tan, Jinyue Yang, Min Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 22, pp. 20258-20274
Closed Access | Times Cited: 1
Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study
Wen Luo, Keyi Li, Chunmei Dai, et al.
Infection (2024) Vol. 52, Iss. 4, pp. 1519-1525
Open Access | Times Cited: 1
Novel compounds with dual inhibition activity against SARS-CoV-2 critical enzymes RdRp and human TMPRSS2
Sameh S. M. Soliman, Alshaimaa M. Hamoda, Yogendra Nayak, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116671-116671
Closed Access | Times Cited: 1
Invalidating betulinic acid as a potential inhibitor against the main protease of SARS-CoV-2 via combined approaches
Jialu Ye, Tao Xu, Rui Zhang, et al.
Steroids (2024), pp. 109522-109522
Closed Access | Times Cited: 1
Insights into targeting SARS-CoV-2: design, synthesis,in silicostudies and antiviral evaluation of new dimethylxanthine derivatives
Abdalla R. Mohamed, Ahmed Mostafa, Mahmoud A. El Hassab, et al.
RSC Medicinal Chemistry (2023) Vol. 14, Iss. 5, pp. 899-920
Open Access | Times Cited: 3
Enhanced expression and solubility of main protease (Mpro) of SARS-CoV-2 from E. coli
Rahul Ahuja, Anupamjeet Kaur, Geetika Kumari, et al.
Protein Expression and Purification (2023) Vol. 211, pp. 106337-106337
Closed Access | Times Cited: 3
Conventional Understanding of SARS‐CoV‐2 Mpro and Common Strategies for Developing Its Inhibitors
Kun Zhou, Daquan Chen
ChemBioChem (2023) Vol. 24, Iss. 22
Closed Access | Times Cited: 3
Structure-Based Lead Optimization of Enterovirus D68 2A Protease Inhibitors
Bin Tan, Chang Liu, Kan Li, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 21, pp. 14544-14563
Closed Access | Times Cited: 3
Crystallographic and biophysical analysis of the fusion core from SARS‐CoV‐2 spike protein
Chun‐Hua Hsu
Journal of the Chinese Chemical Society (2023) Vol. 70, Iss. 5, pp. 1208-1218
Open Access | Times Cited: 2

Scroll to top